T-Cell Therapy Produced Prolonged Remission in Relapsed Pediatric ALL

Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.

Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, discusses the long-term, follow-up data from a trial using CAR T-cell therapy in 39 children and young adults with relapsed, treatment-resistant acute lymphocytic leukemia.

Recent Videos
Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.
In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center .
Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.
Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.
Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.
Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.
Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASH
Related Content
The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

Targeting the Tumor Microenvironment in Lymphoma

Targeting the Tumor Microenvironment in Lymphoma

Stephen M. Ansell, MD, PhD
December 4th 2015
Podcast

In this interview we discuss the role of the tumor microenvironment in Hodgkin and non-Hodgkin lymphoma and research that seeks to disrupt and target this environment as a means of treatment.

Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.

FDA OKs Axatilimab in Pediatric/Adult Chronic GVHD

Ariana Pelosci
August 14th 2024
Article

Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.

New Developments in Multiple Myeloma

New Developments in Multiple Myeloma

Noopur Raje, MD
December 8th 2014
Podcast

In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Russ Conroy
July 24th 2024
Article

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Upon acceptance, the FDA will review the resubmitted application between 2 and 6 months for remestemcel-L in pediatric patients.

BLA Resubmitted for Remestemcel-L in Pediatric Steroid-Refractory GVHD

Russ Conroy
July 10th 2024
Article

Upon acceptance, the FDA will review the resubmitted application between 2 and 6 months for remestemcel-L in pediatric patients.